The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis

BJU International

Volumn 121, Issue 5, 2018, Pages 684-698

  Bhindi, Bimal ^a   Wallis, Christopher J D ^b   Boorjian, Stephen A ^a   Thompson, R Houston ^a   Farrell, Ann ^a   Kim, Simon P ^c   Karam, Jose A ^d   Capitanio, Umberto ^e   Golijanin, Dragan ^f,g   Leibovich, Bradley C ^a   Gershman, Boris ^f,g  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f RHODE ISLAND HOSPITAL   (United States)

^g BROWN UNIVERSITY   (United States)

Author keywords

complications; lymph node dissection; nephrectomy; prognosis; renal cell carcinoma; survival

Indexed keywords

ALL CAUSE MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; KIDNEY METASTASIS; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; META ANALYSIS; NEWCASTLE-OTTAWA SCALE; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RADICAL NEPHRECTOMY; RENAL CELL CARCINOMA; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; MORTALITY; OBSERVATIONAL STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85042585155     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.14127     Document Type: Review

References (77)

1. Clark PE, Agarwal N, Biagioli MC et al. Bladder cancer. J Natl Compr Canc Netw 2013; 11: 446–75
2. Motzer RJ, Jonasch E, Agarwal N et al. Kidney cancer, version 3.2015. J Natl Compr Canc Netw 2015; 13: 151–9
3. Mohler JL, Armstrong AJ, Bahnson RR et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw 2016; 14: 19–30
4. Capitanio U, Becker F, Blute ML et al. Lymph node dissection in renal cell carcinoma. Eur Urol 2011; 60: 1212–20
5. Pantuck AJ, Zisman A, Dorey F et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003; 169: 2076–83
6. Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 1991; 146: 1224–7
7. Herrlinger A, Schrott KM, Sigel A, Giedl J. Results of 381 trans-abdominal radical nephrectomies for renal-cell carcinoma with partial and complete en-bloc lymph-node dissection. World J Urol 1984; 2: 114–21
8. Gilloz A, Tostain J. Comparative study of actuarial survival rates in stage II and III renal cell carcinomas managed by radical nephrectomy alone or associated with formal retroperitoneal lymph node dissection. Prog Clin Biol Res 1982; 100: 489–92
9. Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res 1999; 19(2C): 1573–8
10. Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol 2011; 185: 1615–20
11. Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML. Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol 2008; 180: 99–103
12. Delacroix SE Jr, Chapin BF, Chen JJ et al. Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol 2011; 186: 1236–41
13. Gershman B, Moreira DM, Thompson RH et al. Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection. Eur Urol 2017; 72: 300–6
14. Karakiewicz PI, Trinh QD, Bhojani N et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 2007; 51: 1616–24
15. Blom JH, van Poppel H, Marechal JM et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009; 55: 28–34
16. Feuerstein MA, Kent M, Bazzi WM, Bernstein M, Russo P. Analysis of lymph node dissection in patients with >=7-cm renal tumors. World J Urol 2014; 32: 1531–6
17. Gershman B, Thompson RH, Moreira DM et al. Radical nephrectomy with or without lymph node dissection for nonmetastatic renal cell carcinoma: a propensity score-based analysis. Eur Urol 2017; 71: 560–7
18. Feuerstein MA, Kent M, Bernstein M, Russo P. Lymph node dissection during cytoreductive nephrectomy: a retrospective analysis. Int J Urol 2014; 21: 874–9
19. Gershman B, Thompson RH, Moreira DM et al. Lymph node dissection is not associated with improved survival among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma: a propensity score based analysis. J Urol 2017; 197(3 Pt 1): 574–9
20. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–12
21. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–12
22. Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
23. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses. Ottawa, ON: Department of Epidemiology and Community Medicine, University of Ottawa, 2011. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed August 2017
24. https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/case_series.Accessed August 2017
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60
26. Aziz A, May M, Zigeuner R et al. Do young patients with renal cell carcinoma feature a distinct outcome after surgery? A comparative analysis of patient age based on the multinational CORONA database. J Urol 2014; 191: 310–5
27. Bekema HJ, MacLennan S, Imamura M et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol 2013; 64: 799–810
28. Ristau BT, Manola J, Haas NB et al. Retroperitoneal lymphadenectomy in high-risk non-metastatic renal cell carcinoma: an analysis of the ASSURE (ECOG-ACRIN 2805) adjuvant trial. J Urol 2017; 199: 53–9
29. Capitanio U, Matloob R, Suardi N et al. The extent of lymphadenectomy does affect cancer specific survival in pathologically confirmed T4 renal cell carcinoma. Urologia 2012; 79: 109–15
30. Capitanio U, Suardi N, Matloob R et al. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int 2014; 114: 210–5
31. Joslyn SA, Sirintrapun SJ, Konety BR. Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology 2005; 65: 675–80
32. Sun M, Trinh QD, Bianchi M et al. Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. BJU Int 2014; 113: 36–42
33. Chen ZF, Wu P, Zheng SB, Zhang P, Tan WL, Mao XM. Patient outcome and prognostic factors of renal cell carcinoma in clinical stage T(1-3)N(1-2)M(0): a single-institution analysis. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31: 749–54
34. Dimashkieh HH, Lohse CM, Blute ML, Kwon ED, Leibovich BC, Cheville JC. Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol 2006; 176: 1978–82
35. Ditonno P, Traficante A, Battaglia M, Grossi FS, Selvaggi FP. Role of lymphadenectomy in renal cell carcinoma. Prog Clin Biol Res 1992; 378: 169–74
36. Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. Eur Urol 1997; 31: 40–8
37. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology 1986; 27: 291–301
38. Russell CM, Lue K, Fisher J et al. Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma. BJU Int 2016; 117(6B): E60–6
39. Sun M, Bianchi M, Hansen J et al. Nodal involvement at nephrectomy is associated with worse survival: a stage-for-stage and grade-for-grade analysis. Int J Urol 2013; 20: 372–80
40. Terrone C, Cracco C, Porpiglia F et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006; 49: 324–31
41. Thomas AZ, Adibi M, Borregales LD et al. Surgical management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. J Urol 2015; 194: 316–22
42. Trinh QD, Schmitges J, Bianchi M et al. Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort. BJU Int 2012; 110(2 Pt 2): E21–7
43. Zhang ZL, Li YH, Xiong YH et al. Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma. Chin J Cancer 2010; 29: 995–9
44. Chapman TN, Sharma S, Zhang S, Wong MK, Kim HL. Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. Urology 2008; 71: 287–91
45. Gershman B, Moreira DM, Boorjian SA et al. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol 2016; 69: 84–91
46. Babaian KN, Kim DY, Kenney PA et al. Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol 2015; 193: 1101–7
47. Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 2004; 172: 465–9
48. Capitanio U, Abdollah F, Matloob R et al. When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow-up. BJU Int 2013; 112: E59–66
49. Capitanio U, Deho F, Dell'Oglio P et al. Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion. World J Urol 2016; 34: 1139–45
50. Crispen PL, Breau RH, Allmer C et al. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 2011; 59: 18–23
51. Gershman B, Takahashi N, Moreira DM et al. Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model. BJU Int 2016; 118: 742–9
52. Hutterer GC, Patard JJ, Perrotte P et al. Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram. Int J Cancer 2007; 121: 2556–61
53. Ishikawa Y, Aida S, Tamai S et al. Significance of lymphatic invasion and proliferation on regional lymph node metastasis in renal cell carcinoma. Am J Clin Pathol 2007; 128: 198–207
54. Lee HW, Jeon HG, Jeong BC et al. Diagnostic and prognostic significance of radiologic node-positive renal cell carcinoma in the absence of distant metastases: a retrospective analysis of patients undergoing nephrectomy and lymph node dissection. J Korean Med Sci 2015; 30: 1321–7
55. Bazzi WM, Sjoberg DD, Feuerstein MA et al. Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. J Urol 2015; 193: 1911–6
56. Capitanio U, Abdollah F, Matloob R et al. Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: implications for multimodal therapy. Int J Urol 2013; 20: 572–9
57. Capitanio U, Jeldres C, Patard JJ et al. Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma. BJU Int 2009; 103: 33–7
58. Kroeger N, Pantuck AJ, Wells JC et al. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. Eur Urol 2015; 68: 506–15
59. Kwon T, Song C, Hong JH, Kim CS, Ahn H. Reassessment of renal cell carcinoma lymph node staging: analysis of patterns of progression. Urology 2011; 77: 373–8
60. Lughezzani G, Capitanio U, Jeldres C et al. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. Cancer 2009; 115: 5680–7
61. Messing EM, Manola J, Wilding G et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214–22
62. Pantuck AJ, Zisman A, Dorey F et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003; 97: 2995–3002
63. Patel HD, Gorin MA, Gupta N et al. Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis. Can Urol Assoc J 2016; 10: 389–95
64. Trinh QD, Sukumar S, Schmitges J et al. Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy. Ann Surg Oncol 2013; 20: 2096–102
65. Ward JF, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol 2002; 168: 56–60
66. Ibrahim AH, Ezzat AE. Impact of lymphadenectomy in management of renal cell carcinoma. J Egypt Natl Canc Inst 2012; 24: 57–61
67. Minervini A, Lilas L, Morelli G et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? BJU Int 2001; 88: 169–72
68. Ou YC, Ho HC, Cheng CL, Ka YL, Lin CH, Yang CR. The role of lymphadenectomy in the radical nephrectomy for renal cell carcinoma. Chung Hua I Hsueh Tsa Chih (Taipei) 2001; 64: 215–22
69. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001; 166: 68–72
70. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990; 143: 468–73
71. Studer UE, Scherz S, Scheidegger J et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990; 144(2 Pt 1): 243–5
72. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. Trans Am Assoc Genitourin Surg 1968; 60: 122–9
73. Matsuyama H, Hirata H, Korenaga Y et al. Clinical significance of lymph node dissection in renal cell carcinoma. Scand J Urol Nephrol 2005; 39: 30–5
74. Ravaud A, Motzer RJ, Pandha HS et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016; 375: 2246–54
75. Margulis V, Wood CG. The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. Cancer J 2008; 14: 308–14
76. Karmali RJ, Suami H, Wood CG, Karam JA. Lymphatic drainage in renal cell carcinoma: back to the basics. BJU Int 2014; 114: 806–17
77. Rini BI, Dorff TB, Elson P et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 2016; 17: 1317–24